Investigational drug · Phase 3
Petosemtamab
Also called: MCLA-158, GEN1158
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
5
Any phase or sponsor naming "Petosemtamab"
First trial start
2018
May 2, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Petosemtamab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma
- Colorectal Cancer
- Advanced/Metastatic Solid Tumors
- Gastric Cancer
- Gastroesophageal-junction Cancer
- NSCLC
- HNSCC
- Esophageal Cancer
- Left-sided Colorectal Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Colorectal cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Petosemtamab" as an intervention, largest first.
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)Pivotal-lookingRecruiting
GenmabIndustry
NCT07702032 · 960 participants (planned) · Start Aug 11, 2026 · Primary completion Jul 2029
Drug: Petosemtamab; Cetuximab and 2 more · For: Left-sided Colorectal Cancer
Sites: Hot Springs, Arkansas; Los Angeles, California; Savannah, Georgia · 12 sites in all
- A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Pivotal-lookingActive, not recruiting
GenmabIndustry
NCT06525220 · 699 participants · Start Sep 25, 2024 · Primary completion Jan 2028
Drug: Petosemtamab; Pembrolizumab · For: Head and Neck Squamous Cell Carcinoma
Sites: Mobile, Alabama; La Jolla, California; Los Angeles, California · 202 sites in all
- A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)Pivotal-lookingActive, not recruiting
GenmabIndustry
NCT06496178 · 621 participants · Start Jun 25, 2024 · Primary completion Feb 2028
Drug: Petosemtamab; Investigator's Choice and 2 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Mobile, Alabama; Prescott, Arizona; Scottsdale, Arizona · 188 sites in all
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)Pivotal-lookingRecruiting
GenmabIndustry
NCT07775287 · 600 participants (planned) · Start Oct 7, 2026 · Primary completion Mar 30, 2029
Drug: Petosemtamab; Cetuximab and 5 more · For: Colorectal Cancer
Sites: Hot Springs, Arkansas; Los Angeles, California; Tampa, Florida · 7 sites in all
GenmabIndustry
NCT03526835 · 560 participants (planned) · Start May 2, 2018 · Primary completion May 2028
Drug: MCLA-158 · For: Advanced/Metastatic Solid Tumors; Colorectal Cancer; Gastric Cancer and 5 more
Sites: La Jolla, California; Los Angeles, California; San Diego, California · 54 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antibodies to watch in 2026.
Crescioli S, Kaplon H, Chenoweth A, et al. · MAbs 2026
- Immunotherapeutic strategies in HPV-positive and HPV-negative recurrent/metastatic oropharyngeal squamous cell carcinoma: From PD-1 blockade to EGFR-directed bispecifics and therapeutic HPV vaccines.
Di Bello A, Gili R, Falcicchia R, et al. · Crit Rev Oncol Hematol 2026
- Recent highlights and breakthroughs in immunotherapy for head and neck cancers.
Vuille JA, Szturz P · Curr Opin Oncol 2026
- Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers.
Carosi F, Filippini DM, Fabbri L, et al. · Crit Rev Oncol Hematol 2026
- LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
Machiels JP, Fayette J, Haddad R, et al. · Future Oncol 2025
- Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications.
Lundberg AS, Geuijen CAW, Hill S, et al. · Cancers (Basel) 2025
Also in development for Head and Neck Squamous Cell Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.